---
schema_version: "secwatch.filing_event.v1"
accession: "0000950123-24-005877"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:14:34.739034+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics appoints Julianne Bruno as COO effective May 23, 2024

## Summary
- Bruno previously SVP and Head of Programs & Portfolio; led hemoglobinopathy partnership with Vertex.
- Annual salary of $460,000, target bonus 45% of base, and eligible for equity plans.
- Received one-time grant of 20,000 RSUs vesting over 4 years (25% annually).
- Employment agreement provides 6-month notice period; 12-month notice and accelerated vesting after change in control.
- Bruno holds MBA from Wharton, AB from Princeton; prior McKinsey biotech practice leader.

## SEC filing metadata
- accession: 0000950123-24-005877
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095012324005877/0000950123-24-005877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095012324005877/crsp-20240523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950123-24-005877
- JSON: https://secwatch.observer/filing/0000950123-24-005877.json
- Plain text: https://secwatch.observer/filing/0000950123-24-005877.txt

## Key facts
- Executive change
  Julianne Bruno was appointed as Chief Operating Officer at CRISPR Therapeutics AG.
  - Action: promoted
  - Role: Chief Operating Officer
  source text: On May 23, 2024, CRISPR Therapeutics AG (the “Company”) announced the promotion of Julianne Bruno, currently the Company’s Senior Vice President and Head of Programs & Portfolio, to be the Company’s Chief Operating Officer effective as of May 23, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000095012324005877/0000950123-24-005877-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.